PPARG and diabetes mellitus: Some traditional hypoglycemic drugs(HD) have shown good cardiovascular safety (7–9), especially the clinical application of novel types of hypoglycemic drugs, including dipeptidyl peptidase-4 inhibitor (DPP-4i), glucagon like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter-2 inhibitor (SGLT-2i), peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has ushered in a new era of diabetes treatment.